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1 Zusammenfassung 
Adoptiver T-Zelltransfer ist ein Therapieverfahren, bei dem Patienten-eigene 
T-Lymphozyten mit einem tumorspezifischen Rezeptor transduziert werden, um 
eine anti-tumorale Aktivität zu induzieren 
 
Trotz vieler Fortschritte birgt dieses Verfahren auch Risiken. Eines ist die 
Bildung autoreaktiver T-Zellen: Die Erkennungsdomäne des T-Zellrezeptors ist 
ein Dimer aus α- und β-Kette. Daher kann, durch Hinzufügen eines zweiten 
T-Zellrezeptors in eine T-Zelle, ein weiteres Dimer aus einer nativen und einer 
exogenen Kette entstehen. Ein solcher, fehlgepaarter (’mispaired’) Rezeptor 
kann potenziell neue Antigene erkennen und Autoimmunreaktionen auslösen.  
 
Gegenstand der vorliegenden Arbeit ist es eine neuartige 
T-Zellrezeptormodifikation zum Unterbinden von Mispairing zu untersuchen. 
Dazu vertauschten wir die konstante oder die variable Domäne zwischen den 
Ketten (’domain crossover’). Dieses Prinzip wird bereits erfolgreich beim Design 
von bispezifischen Antikörpern eingesetzt, um Mispairing zu vermeiden und 
könnte sich dank großer Homologie auf T-Zellrezeptoren übertragen lassen. 
 
Bei Transduktion der gekreuzten Rezeptorketten in murine T-Zellen, stellten wir 
zunächst keine Oberflächenexpression, jedoch eine intrazelluläre Akkumulation 
von gekreuzten α-Ketten fest. Nach Beseitigung einer Interferenz durch die 
Linkersequenz stellte sich eine temporäre Oberflächenexpression der α-Kette 
des gekreuzten Rezeptors ein. Transduzierten wir jedoch nur eine einzelne 
Kette, so war keine Oberflächenexpression nachweisbar. Wir folgerten, dass 
auch die grundsätzlich nicht mehr detektierbare β-Kette exprimiert wird und sich 
gekreuzten Ketten erfolgreich mit CD3 Untereinheiten zusammensetzen.  
 
Um eine stabile Oberflächenexpression zu ermöglichen, fügten wir 
Disulfidbrücken ein und veränderten die genaue Kreuzungsstelle innerhalb der 
Ellbogenregion, welche die variable und konstante Domäne verbindet. Es ließ 
sich jedoch keine dauerhafte Oberflächenexpression erzielen. Somit sind 
andere Strategien erforderlich um Mispairing zu verhindern oder zu reduzieren.
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2 Abstract 
Adoptive T cell transfer is a novel approach for cancer treatment in which 
patient’s T lymphocytes are extracted and genetically modified to redirect these 
against the cancer cell. 
 
However, there are still a number of risks and limitations to this approach. One 
is the formation of autoreactive T cell: The antigen-recognizing part of the T cell 
receptor is a dimer of an α- and a β-chain. Accordingly, transduced T cells can 
express ‘mispaired’ T cell receptors that comprise a native and an exogenous 
chain. These heterodimers can cause autoimmunity if they target self-antigens.  
 
The aim of this study was to investigate a novel approach against mispairing by 
transferring either the variable or the constant domain of one chain across to 
the other chain. This concept is already successfully employed in the design of 
bispecific antibodies to avoid mispairing and may be transferable due to a high 
degree of homology between T cell receptors and antibodies. 
 
The transduction of crossed receptors into murine T cells did not result in any 
surface expression. We observed an intracellular accumulation of α-chains. 
After a redesign eliminating an interference with the linker sequence, we found 
a temporary surface expression of α-chains in one of our constructs. However, 
when transducing only the single chain, we could not detect surface expression. 
We concluded that, while undetectable, the β-chain must be expressed when 
transducing with the bicistronic vector and that the crossed T cell receptor 
assembles correctly with the CD3 subunits.  
 
Finally, we aimed at stabilizing surface expression of the crossed receptor. We 
added an additional disulfide bond between both chains at different locations 
and changed the exact location of the domain cross-over in the so-called elbow 
region, which links the variable and the constant domain of each chain. Yet, a 
sustained surface expression of crossed T cell receptors could not be achieved. 
Alternative strategies are thus needed to prevent TCR mispairing.
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3 Introduction 
3.1 Cancer immunotherapy 
Adoptive cell therapy (ACT) is a highly promising, however not yet approved 
form of cancer immunotherapy (Pedrazzoli et al. 2012). In ACT, tumor-specific 
cytotoxic T cells are expanded and stimulated in vitro to elicit an antitumoral 
response upon reinfusion to the patient. Clinical studies have shown the 
efficacy of this approach even in patients with advanced and refractory disease 
(Rosenberg et al. 1988, Dudley et al. 2002) 
 
In clinical studies, two main approaches are employed to generate the required 
T cell population: Isolating and expanding pre-existing tumor-specific 
lymphocytes ex vivo or genetic modification of T cells that are initially not 
tumor-reactive (Pedrazzoli et al. 2012). The former relies on isolation of 
tumor-infiltrating lymphocytes (TIL) out of tumorous tissue (Wu et al. 2012) - a 
process which is considered a critical limitation to TIL-based ACT, as many 
tumor entities do not possess sufficiently many TIL to allow for ex vivo 
extraction (Restifo et al. 2012). This limitation is overcome by the latter 
approach: In gene transfer-based ACT (gtACT), patients’ T cells are genetically 
engineered to become tumor-reactive. This is commonly achieved by either 
transferring a tumor-specific TCR or a chimeric antigen receptor (CAR), 
directing cytotoxic T cells towards the tumor (Sadelain et al. 2003, Hughes et al. 
2005).  
 
However, both forms of ACT share other considerable limitations regarding 
effectiveness and safety. As ACT critically depends on antigen recognition and 
T cell activation, tumors that impair either of these pillars can escape an 
effective T cell response: Tumors can circumvent antigen recognition by either 
loss of target antigens (Maeurer et al. 1996) or a downregulation of major 
histocompatibility complex class I expression (MHC I) (Ferrone et al. 1995, 
Restifo et al. 1996). Also, it has been shown that a variety of tumors create an 
immunosuppressive milieu by soluble and membranous molecules such as 
Introduction 
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transforming growth factor β (TGFβ) or programmed death ligand 1 (PD-L1) 
(Dougan et al. 2009), as well as recruitment of immune-regulatory cells like 
regulatory T cells (Treg) (Antony et al. 2005) or myeloid derived suppressor 
cells (MDSC) (Payne et al. 2012). In solid tumors, poor access to the cancerous 
compartment, leading to “immunological ignorance” is also considered a 
relevant hurdle to an efficient anti-tumoral T cell response (Ochsenbein et al. 
1999).  
 
Some of these limitations can be addressed by a lymphodepleting pretreatment, 
which has significantly increased the initial response rate up to 72% and has 
even resulted in long-term regressions (Dudley et al. 2008, Rosenberg et al. 
2011). Lymphodepletion, either by total body irradiation (TBI) or chemotherapy, 
is thought to enhance ACT by the following mechanisms: For one, it creates a 
niche in lymphatic organs and bone marrow for transferred T cells to proliferate 
and persist (Dudley et al. 2002). Secondly, it decreases the number of 
immunosuppressive cells fostering a stronger antitumoral response (Gattinoni et 
al. 2005, Kmieciak et al. 2011). And finally, it is believed, that the induced tissue 
damage leads to the release of proinflammatory cytokines, which in turn attract 
immune cells to the location of the tumor (Payne et al. 2012). 
 
Yet, safety concerns remain: The two most important dangers are the creation 
of autoreactive T cells and the malignant degeneration of the infused 
lymphocytes. While the first is usually explained by off-target reactivity causing 
damage to healthy tissue and a potentially lethal “cytokine storm” (Schumacher 
2002, Riechelmann et al. 2007), the latter is due to the highly active viral 
promoters, randomly inserted into the cells genome, potentially activating 
oncogenes or causing insertional mutagenesis (Woods et al. 2003). When 
contemplating the risk of autoreactive T cells in gtACT, the main consideration 
is the target antigen. It requires careful selection and extensive research to 
choose an antigen which is expressed on as many cancer cells as possible, but 
at the same time remaining specific.  
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3.2 T cell receptor mispairing 
Even with the most careful selection of cancer antigen, the danger of 
self-reactivity cannot be completely contained in gtACT. This is due to the 
structure of the TCR: The TCR is a multimer, comprising a heterodimer of two 
chains, the alpha (TCRa) and the beta (TCRb) chain, which together recognize 
an antigen fragment in the context of a MHC-I molecule. When transducing a 
T cell with a cancer specific TCR, the expression of the endogenous TCR is 
unaffected. Hence, a transduced T cell expresses two different TCRa and 
TCRb chains each. However, these four proteins cannot only form two 
functional TCR, but four: Next to an all-endogenous and an all-exogenous TCR, 
two further TCR can form by heterodimerization of an endogenous and an 
introduced chain. It was long hypothesized that these mispaired TCR (often 
referred to as heterodimeric TCR) could potentially recognize MHC-I coupled 
self-antigens (Merhavi-Shoham et al. 2012), even when neither the 
endogenous, nor the introduced TCR would do so (Figure 1).  
Introduction 
 
 
 
-8- 
 
 
Figure 1: T cells transduced with a cancer-specific TCR can become autoreactive: Even though 
neither the original (right), nor the introduced TCR (top) recognize self-antigens, T cells can attack healthy 
cells because of mispaired TCR chains (left and bottom) (Engels et al. 2007).  
 
For a long time, this effect has been a subject of discussion as – though in 
theory plausible – it was never directly proven. In 2010 Bendle et al. brought 
forward compelling evidence that mispairing can cause severe toxicity in a 
mouse model. Their group described an effect, which they named TCR gene 
transfer-induced graft-versus-host disease (TI-GVHD). In their study, mice 
treated with TCR-transduced T cells followed by an IL-2 regimen experienced 
severe autoimmune reaction and had a close to 100% mortality within days 
after treatment. Further investigations demonstrated that this was also true for 
T cells which were only transduced with either TCRa or TCRb alone (Bendle et 
al. 2010). As TCR surface expression is tightly controlled within T cells and 
dependent on correct TCR-CD3 subunit assembly, a single TCRa or TCRb will 
be retained within cells (Bonifacino et al. 1989). This in turn means that a 
TCR-mediated autoimmune reaction in the setting of single-chain transfer can 
only be explained by a heterodimerization of endogenous and introduced chain. 
The said publication also showed, that when using a modified TCR with 
somewhat better pairing properties, toxicity could be reduced.  
CD#8+&T#Cell&
Introduced&
cancerspecific&TCR&
Tumor&Cell&
Healthy&Cell&Healthy&Cell&
Self&an>gen&
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In addition, the expression level of an introduced TCR is reduced by mispairing 
with an endogenous TCR and heterodimers competing for CD3 assembly. Yet 
the expression level of a TCR is crucial for T cell function (Labrecque et al. 
2001). So, next to potential danger of autoimmunity, mispairing may also limit 
effectiveness of TCR gene transfer. 
 
Several attempts have been made to tackle this problem. Some approaches 
aim at limiting heterodimerization by preferential pairing via additional disulfide 
bonds (Cohen et al. 2007, Kuball et al. 2007) or partial murinization (Cohen et 
al. 2006). Others diverge more strongly from the natural TCR structure by 
creating fused TCR-CD3ζ proteins (Willemsen et al. 2000) or single chain TCR 
(Figure 2) (Bendle et al. 2009). All of these modifications showed less 
mispairing, however only the single chain and the TCR-CD3ζ approach abolish 
mispairing completely (Zhang et al. 2004, Sebestyen et al. 2008). In turn, with 
more structural differences to a native TCR, there is a possible decrease in 
sensitivity (Zhang et al. 2004) and higher potential for immunogenicity (Uckert et 
al. 2009). 
 
Figure 2: Possible modifications of a native TCR to reduce or avoid mispairing. (A) Native TCR. (B) 
Additional disulfide bond. (C) Murinization of constant domains. (D) TCR-CD3ζ fusion protein. (E) Single 
chain TCR (Govers et al. 2010). 
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3.3 Crossed monoclonal antibodies 
Another - albeit less severe - case of mispairing exists in biotechnology: When 
producing unmodified bispecific antibodies by hybridoma cell lines (so called 
‘quadromas’) two heavy and two light chains are produced. The formation of the 
desired bispecific antibody depends solely on correct pairing. Without further 
optimization, the yield of the desired antibody is only one tenth of all produced 
immunoglobulin (Milstein et al. 1983) (Figure 3).  
 
Figure 3: Four of the twelve possible products when producing a desired (A) bispecific antibody. 
The three undesired side products (B-D) result from mispairing of light chains. The other side products (not 
shown) result from homodimerization of two identical heavy chains (Schaefer et al. 2011).  
 
Schaefer et al. showed that the possible mispairing between heavy and light 
chains can be completely abolished by a crossover of either the variable or the 
constant domains in one antibody arm. The function of such a “CrossMab” is 
not impaired compared to the unmodified antibody (Schaefer et al. 2011). 
Schaefer et al. hypothesized that chain alignment works by specific steric 
interactions of the different domains to their partner domain. That is, a domain 
of a heavy chain can only pair with the corresponding domain of a light chain. 
Therefore, a crossover of domains prevents a pairing of a crossed and an 
uncrossed chain (Figure 4). 
 
   
Figure 4: Domain crossover abolishes mispairing of heavy and light chains in bispecific 
antibodies. Crossing domains of heavy and light chains among each other (B) prevents unwanted 
heterodimerization of heavy and light chains (i.e. yellow-blue and turquoise-red), which occurs in 
unmodified antibodies (A) (Schaefer et al. 2011). 
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3.4 Rationale and goals 
Since TCR chains and light chains of antibodies both belong to the 
immunoglobulin superfamily (Barclay 2003), the approach described above may 
well translate to mispairing of TCR. In order to evaluate this hypothesis, we 
designed two “CrossTCR” (xTCR) and assessed their pairing properties and 
functionality. 
 
 
Figure 5: xTCR: By exchanging either the constant (B) or the variable domain (C) of an unmodified TCR 
(A) two xTCR were designed, to examine their pairing properties and functionality the specific steric 
interactions between the domains (displayed as ‘knob in hole’) should prevent mispairing of crossed and 
uncrossed chains.  
 
As a model, we chose the MHC class I-restricted, ovalbumin-specific TCR 
(OT-I TCR). We considered this the optimal candidate for several reasons: The 
OT-I model is one of the most common models for testing ACT in mice. There 
are cancer cell lines such as the Panc-OVA that specifically overexpress the 
recognized OVA peptide, creating an ideal testing ground for ACT in a mouse 
tumor model (Kobold et al. 2015). Furthermore, the OT-I TCR showed severe 
TI-GVHD in the work Bendle et al., supplying an in vivo model to test for 
mispairing side effects. And finally, this approach also allowed for a direct 
analysis of chain expression via flow cytometry, as there are commercially 
available antibodies that detect the OT-I TCR α- (i.e. anti-Vα2) and TCRβ-chain 
(i.e. anti-Vβ5) (de Witte et al. 2008).  
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In this thesis, the following questions will be addressed:  
1. Can crossed T cell receptors be stably transduced into primary murine 
T cells?  
2. Do transduced T cells show surface expression of xTCR?  
3. How does the location of domain crossing affect surface expression? 
4. Do additional disulfide bonds change xTCR surface expression? 
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4 Materials 
4.1 Chemicals 
Table 1: List of chemicals 
Acetic acid Merck, Darmstadt 
Agarose Biozym Scientific, Oldendorf 
Calcium chloride Merck, Darmstadt 
Chloroquine Merck, Darmstadt 
Dimethyl sulfoxide (DMSO) Sigma, Steinheim 
Disodium hydrogen phosphate 
monohydrate 
Merck, Darmstadt 
Glycerol Carl Roth GmbH, Karslruhe 
Isoflurane Abbott, Zug 
Magnesium chloride Carl Roth GmbH, Karslruhe 
Potassium acetate Carl Roth GmbH, Karslruhe 
Potassium chloride Merck, Darmstadt 
Rubidium chloride Carl Roth GmbH, Karslruhe 
Sodium chloride Carl Roth GmbH, Karslruhe 
Trypan blue Sigma, Steinheim 
 
4.2 Antibodies 
Table 2: List of antibodies 
Antibody Stock concentration Manufacturer Clone 
Anti-Mouse CD3ε 1.0 mg/ml eBioscience 145-2C11 
Anti-Mouse CD28 1.0 mg/ml eBioscience 37.51 
FITC Rat Anti-
Mouse Vα2 TCR 
0.5 mg/ml BD Pharmingen B20.1 
PE Mouse Anti-
Mouse Vβ 5.1, 5.2 
TCR 
0.2 mg/ml BD Pharmingen MR9-4 
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4.3 DNA Primers 
Table 3: List of Primers 
pMP71 seq fwd 5’-CAG CAT CGT TCT GTG TTG-3’ 
pMP71 seq rev 5’-CAT TTA AAT GTA TAC CCA AAT CCA-3’ 
OT-I seq centre 5’-CTG GTC CAA CCA GAC CAG CTT CAC ATG CC-3’ 
OT-I co seq centre 5’-AGC AAC TAC AGC TAC TGC CTG AG-3’ 
OT-Iα NotI fwd 5’-ATT AGC GGC CGC GCC ACC ATG GAC AAG ATC CTG-3’ 
OT-Iα p2A rev 5’-CAA AGT CTG TTT CAC CGG GCT GCT CCA CAG CCT CAG-3’ 
p2A OT-Iα fwd 5’-CTG AGG CTG TGG AGC AGC CCG GTG AAA CAG ACT TTG-3’ 
p2A OT-Iβ rev 5’-AGC ACC CGC GGG GCC ATT GGG TTG GAC TCC ACG T-3’ 
OT-Iβ p2A fwd 5’-ACG TGG AGT CCA ACC CAA TGG CCC CGC GGG TGC T-3’ 
OT-Iβ EcoRI rev 5’-TAA TGA ATT CTC AGC TGT TCT TCT TCT TCA CCA-3’ 
OT-Iβ NotI fwd 5’-ATT AGC GGC CGC GCC ACC ATG GCC CCG CG-3’ 
OT-Iβ p2A rev 5’-GCT GCC GCT GCT GTT CTT CTT CTT CAC CA-3’ 
p2A OT-Iβ fwd 5’-AAG AAG AAC AGC AGC GGC AGC GGC GC-3’ 
p2A OT-Iα rev 5’-ATC TTG TCC ATG GGC CCA GGG TTT TCC TC-3’ 
OT-Iα p2A fwd 5’-CCC TGG GCC CAT GGA CAA GAT CCT GAC CG-3’ 
OT-Iα EcoRI rev 5’-TAA TGA ATT CTC AGC TGC TCC ACA GCC-3’ 
scOT-Iα co Not-I fwd 5’-ATT AGC GGC CGC GCC ACC ATG GAT AAG ATC CTG ACC GCC-3’ 
scOT-Iα c/v EcoRI rev 5’-TAA TGA ATT CTC AGC TGG ACC ACA GCC GC-3’ 
scOT-Iα va Not-I fwd 5’-ATT AGC GGC CGC GCC ACC ATG GCT CCT AGG GTG CTG G-3’ 
scOT-Iβ co NotI fwd 5’-ATT AGC GGC CGC GCC ACC ATG GCC CCT AGG GTG-3’ 
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scOT-Iβ va NotI fwd 5’-ATT AGC GGC CGC GCC ACC ATG GAC AAG ATC CTG ACC GC-3’ 
Signal-β myc-tag rev 5’-CCT CCT CGC TGA TCA ACT TCT GCT CGG TGA CCC AGC TCA GCA G-3’ 
v-β myc-tag fwd 5’-AGA AGT TGA TCA GCG AGG AGG ACT TGG TGT TTC TGC TGG GCA CC-3’ 
OTIβ c/v p2A rev 5’-TGC CGC TGC TGT TCT TCT TCT TGA CCA TG-3’ 
p2A OT-Iα co rev 5’-CTT ATC CAT GGG CCC AGG GTT TTC CT-3’ 
p2A OT-Iα va rev 5’-GGA GCC ATG GGC CCA GGG TTT TCC-3’ 
OT-Iα co p2A fwd 5’-CCT GGG CCC ATG GAT AAG ATC CTG ACC GC-3’ 
OT-Iα va p2A fwd 5’-TGG GCC CAT GGC TCC TAG GGT GCT GG-3’ 
OT-I ba c/v F131 fwd 5'-AGC AGT ATT GTG GCC CTG GCA CGC G-3' 
OT-I ba c/v F131 rev 5'-CCA GGG CCA CAA TAC TGC TCG TAG TTG GCC CG-3' 
OT-I ba va Y148 fwd 5'-CGC CGT GTG CCA GCT GAA GGA CCC CAG AA-3' 
OT-I ba c/v S157 rev 5'-CGG CCT TGC AAG GCT CGA ACA GGG ACA C-3' 
OT-I ba c/v G71 fwd 5'-CGG CGA GTG TCC TGC CCT GCT GAT CTC CAT C-3' 
OT-I ba c/v G71 rev 5'-GGG CAG GAC ACT CGC CGG GGA ACT GCT-3' 
OT-I ba va Y186 rev 5'-CCA GCA CGC ACT TGT CGG TGA TGA AGG TGC-3' 
OT-I ba c/v S197 fwd 5'-CGG CGT GTG CAC CGA TCC CCA GGC CT-3' 
OT-I ba c/v S197 rev 5'-GAT CGG TGC ACA CGC CGC TGT GCA CC-3' 
OT-I ba co Y148 fwd 5'-CGC CGT GTG CCA GCT GAA GGA CCC TAG-3' 
OT-I ba co Y186 fwd 5'-CCG ATA AGT GCG TGC TGG ACA TGA AGG CCA-3' 
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4.4 Enzymes 
Table 4: List of Enzymes 
Pfu DNA polymerase Thermo Scientific 
NotI Thermo Scientific 
EcoRI Thermo Scientific 
T4 DNA ligase Thermo Scientific 
Taq DNA polymerase Thermo Scientific 
 
4.5 Commercial kits 
Table 5: List of commercial kits 
JetQuick® Gel Extraction Spin Kit Genomed, Löhne 
GeneJET Plasmid Miniprep Kit Thermo Scientific 
PureYield™ Plasmid Maxiprep System Promega 
Plasmid Maxi Kit  QIAGEN 
 
4.6 Buffers 
Table 6: List of buffers 
Phosphate buffered saline (PBS) PAA, Paschin 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
Sigma, Steinheim 
 
4.7 Media and cell culture supplements 
4.7.1 Ingredients 
Table 7: List of cell culture media and other additives 
Dulbecco’s modified Eagles Medium 
(DMEM)  
PAA, Pasching  
Roswell Park Memorial Institute 1640 
Medium (RPMI) 
PAA, Pasching  
Penicillin/Streptomycin (100x) PAA, Pasching  
L-Glutamine 200mM PAA, Pasching  
Fetal bovine serum (FBS) Invitrogen, Auckland 
Sodium pyruvate Biochrom AG, Berlin 
G 418 disulfate salt Sigma, Steinheim 
Puromycin Sigma, Steinheim 
Blasticidin Sigma, Steinheim 
β-mercaptoethanol Sigma, Steinheim 
RetroNectin® Clontech, Mountain View 
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4.7.2 Prepared media mixtures 
Table 8: List of cell culture mixtures 
Complete DMEM DMEM 
+10% FBS 
+1% L-glutamine 
+1% Penicillin/streptomycin 
Complete RPMI 1640 RPMI 1640 
+10% FBS 
+1% L-glutamine 
+1% Penicillin/streptomycin 
Plat-E medium Complete DMEM 
+10 µg/ml blasticidin 
+1 mg/ml puromycin 
Plat-E hunger medium DMEM 
+3% FBS 
+1% L-Glutamine 
+1% Penicillin/streptomycin 
T cell medium Complete RPMI 
+1% Sodium pyruvate 
+0.1% HEPES buffer 
OVA selection medium Complete DMEM 
+1 mg/ml G 418 
4.8 Cell lines 
4.8.1 Platinum E 
The Plat-E cell line is based on the traditionally used 293T cell line and is used 
as a packaging cell line to produce ecotropic retrovirus to transduce murine 
cells (Morita et al. 2000). Plat-E cells were kept in Plat-E medium described 
above. Plat-E cells were kindly provided by Matthias Leisegang, Berlin, 
Germany. 
4.9 Devices 
Table 9: List of technical devices 
Flow cytometer FACS Canto II (BD) 
PCR thermocycler T3 Thermocycler (Biometra) 
Photometer NanoPhotometer® (IMPLEN) 
CO2 incubator BD6220 (Heraeus) 
Laminar flow cabinet Lamin Air (Heraeus) 
Neubauer chamber Optik Labor Frischknecht 
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4.10 Computer Software 
Table 10: List of computer software 
Flow cytometry analysis FlowJo (Treestar) 
Molecular cloning Lasergene Suite (DNA star) 
Sequencing results evaluation Lasergene Suite (DNA star) 
DNA melting temperature calculation http://www.appliedbiosystems.com/ 
support/techtools/calc/ 
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5 Methods 
5.1 Production of competent DH5α E. coli 
Bacteria were expanded in 100 ml lysogeny broth (LB) at 37°C to an optical 
density of 0.40 - 0.55. The medium was then cooled down to 4°C and bacteria 
were pelleted by centrifugation at 4°C. Supernatant was removed and the 
bacteria were resuspended in 30 ml of transformation buffer 1. After 5 minutes 
of incubation at 4°C, bacteria were pelleted once more by centrifugation at 4°C. 
Finally, the pellet was resuspended in 4 ml transformation buffer 2 and aliquots 
of 50 – 100 µl were frozen in a liquid nitrogen bath. Hereafter, aliquots were 
stored at -80°C.  
 
5.2 Primer design 
All PCR primers were designed using the DNASTAR Lasergene software suite. 
When calculating the melting temperature of primers only the annealing part of 
the primer was considered. Calculation was performed using the tm calculator 
on www.appliedbiosystems.com/support/techtools/calc. The target annealing 
temperature for every primer was between 60°C and 65°C.  
 
If, in addition to amplification, an extension by a certain nucleotide sequence 
was required, primers were designed, comprising two functionally different 
parts: A 3’ end, annealing to the DNA template, and a 5’ end, consisting of the 
intended extension sequence.  
 
5.3 Polymerase chain reaction for molecular cloning 
In all Polymerase chain reactions (PCR) performed for molecular cloning 
purposes, only DNA polymerases with proofreading activity were used. The 
reaction mix was set up in the following way: 
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 Table 11: PCR reaction mix 
Component Amount 
Template DNA 50-500 ng 
10x Pfu Buffer + MgSO4 5 µl 
Primers 50 pmol each 
dNTPs 10 nmol each 
Pfu DNA polymerase 2.5 U 
H2O Filled up to 50 µl 
 
The temperature cycling parameters were: 
 
Table 12: PCR cycling parameters 
Temperature (step) Duration   
95°C (initial denaturation) 5 min   
95°C (denaturation) 0.5 min 
 
 
Tm – 5°C (annealing) 0.5 min  30 - 35 cycles 
72°C (elongation) 2 min/kb  
72°C (final elongation) 10 min   
 
Next to a simple amplification of the desired DNA fragment, the PCR was also 
used to add short oligonucleotide sequences to the desired fragment. This was 
achieved by using the primer design described in 5.2. 
 
Furthermore, PCRs were also utilized to link distinct PCR products together by 
the so-called overlap extension technique. For this method two sequential 
PCRs are performed: In a first PCR, each of the desired fragments is not only 
amplified, but also extended by a matching sequence. This creates an overlap 
between the two products.  
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Figure 6: Step 1 of overlap extension PCR: The two inside primers contain a not annealing part (green) 
by which the two templates (blue) get extended.  
 
In the second PCR, the two products are combined with the two outside 
primers. Next to an amplification of the template strands, this PCR also yields a 
DNA fragment, which consists of the two templates linked to each other, 
because of their ability to also prime each other.  
 
Figure 7: Step 2 of overlap extension PCR: In the second step, only the two outer primers (red) from 
step 1 are used. On the inside the extensions (green) from step one anneal and function as primers. This 
step yields a fusion of the two initial templates.  
 
After every PCR, an agarose gel electrophoresis was performed and the correct 
band was excised and purified using the JetQuick® Gel Extraction Spin Kit 
according to the manufacturer’s protocol.  
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5.4 DNA agarose gel electrophoresis 
For agarose gels, 1.2 - 3.0 g of agarose were dissolved in 150 ml 
tris-acetic acid-EDTA (TAE) buffer, heated to boiling point and poured into a 
plastic chamber. Ethidium bromide (0.5 µg/ml) was added and evenly 
distributed among the liquid. After adding the adequate amount of loading dye, 
samples were filled into the gel pockets and separated at 90 - 100 V. Fragment 
size was determined by comparison to a DNA ladder on the gel.  
 
5.5  Sticky end ligation 
In order to perform sticky end ligation, insert DNA and vector backbone were 
first digested with two restriction endonucleases. Any digestion with restriction 
enzymes was performed according to manufacturer’s recommendation, found 
on www.thermoscientificbio.com/webtools/doubledigest. Digestion time was 
varied between one and four hours. The reaction mix was incubated at 37°C 
and was composed as follows: 
 
Table 13: DNA digestion reaction mix 
Component Amount 
DNA 500 - 1500 ng 
Recommended 10x buffer 2 µl 
Restriction enzymes 10 U each 
H2O Filled up to 20 µl 
 
Digested vector backbone was always purified via agarose gel electrophoresis 
to clear out the excised former insert. Digested PCR products were directly 
purified by using the JetQuick® Gel Extraction Spin Kit together with JetQuick® 
DNA CleanUp Buffers according to the manufacturer’s protocol.  
 
Finally, the following ligation reaction mix was set up: 
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Table 14: DNA ligation reaction mix 
Component Amount 
Vector DNA (digested) Up to 1 mg 
Insert DNA (digested) Up to 500 µg 
10x T4 DNA ligase buffer 2 µl 
H2O Filled up to 20 µl 
 
After 20 - 30 minutes of incubation at room temperature, 10 µl of the reaction 
mix were used to transform 100 µl competent DH5α E. coli. Competence was 
induced by preparing E. coli as described in 5.1 and by a 45 second heat shock 
at 42°C. After 30 - 60 minutes of pre-incubation in LB, bacteria were centrifuged 
at 400 G for 5 minutes and finally evenly distributed on LB agar plates 
containing selection antibiotics.  
5.6 Cell culture 
Cells were always cultured at 37°C under 5% CO2 and 95% humidity 
atmosphere. Cells were kept in sterile disposable tissue culture treated flasks or 
well plates. All cell culture related work was performed with sterile instruments 
under a laminar flow hood. Whenever cells were spun down this was done by 
centrifugation at room temperature and 400 G for 5 minutes. Any exceptions are 
explicitly denoted. 
 
5.7 Cell counting and viability assessment 
Cell concentration was determined by adding a certain volume of a trypan blue 
solution. Only intact cell membranes prevent the blue dye from crossing into the 
cytoplasm, resulting in a blue staining of dead cells. The concentration of viable 
cells can then be assessed by counting in a hemocytometer. 
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5.8 Splenocyte isolation  
For splenocyte isolation a mouse of the desired genotype was euthanized 
under isoflurane anesthesia. The spleen was then harvested via a flank section, 
remaining soft tissue was carefully removed without rupturing the capsule. For 
transport the organ was kept in T cell medium. Hereafter, a splenocyte 
suspension was generated by meshing the spleen through a 40 µm cell strainer 
and rinsing the strainer several times with T cell medium. The medium passing 
the strainer was collected in a 50 ml tube and centrifuged. The resulting pellet 
was resuspended in erythrocyte lysis buffer and incubated for 90 seconds. The 
lysis reaction was stopped by adding 35 ml T cell medium. The cells were then 
spun down again and re-suspended in T cell medium.  
 
5.9 Production of retroviruses 
On day before transfection 1 - 1.5 x 106 Platinum-E cells (Morita et al. 2000) 
were plated in a well of a tissue culture treated 6-well plate using 3 ml of 
complete DMEM. The next day, when cells had reached 70 - 90% confluency, 
the following plasmid solution was prepared.  
 
Table 15: Plasmid solution 
 Amount (absolute) Concentration 
Retroviral vector 18 µg 120 ng/µl 
CaCl2 30 µmol 200 mM 
Chloroquine 38 nmol 253 µM 
Sterile H2O Filled up to 150 µl  
 
While incubating the plasmid solution for five minutes, the medium on the Plat-E 
cells was removed, carefully replaced by Plat-E hunger medium and the cells 
were placed back in the incubator. A sterile 13 ml polystyrene tube was then 
filled with 150 µl of transfection buffer and the plasmid solution was added 
dropwise while constantly vortexing the tube. The combined solution was 
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incubated for 30 minutes at room temperature and finally added to a well with 
Plat-E cells. 
 
Six hours later the medium was exchanged for Plat-E transfection medium.  
After another 42 hours, the virus containing supernatant was harvested and 
cleared of cells and cellular debris by passing it through a low protein binding 
0.45 µm filter. Hereafter Plat-E cells were supplied with T cell medium. After 
another 24 hours, more the virus harvest procedure from above was repeated.  
 
Collected virus containing supernatant was directly used for transduction 
purposes. 
 
5.10 Transduction of primary murine T cells  
One day before transduction, freshly isolated splenocytes were plated at a 
concentration of 2 x 106 cells/ml in T cell medium supplemented with 
50 µM β-mercaptoethanol, 10 U/ml IL-2, 1 µg/ml activating anti mouse CD3ε 
and 0.1 µg/ml anti mouse CD28 antibody. Cells were then incubated for 
24 hours. 
 
The different media used during the entire procedure selectively expand CD8+ 
cytotoxic T-lymphocytes, while depriving most other cells of necessary survival 
signals. This way a highly pure (> 99%) cytotoxic T lymphocyte population is 
obtained from the initial mix of splenocytes. 
 
The following day a tissue culture treated 24-well plate was coated with 
400 µl RetroNectin® per well (stock concentration: 6.25 μg/ml). After 2 hours of 
incubation at room temperature the RetroNectin was removed and wells were 
blocked for 30 minutes at 37°C using 500 µl of sterile filtrated 2% BSA solution 
per well. Hereafter, the BSA containing solution was removed and each well 
was washed once with 2 ml PBS containing 25 mM HEPES. 
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Depending on viral titers 1-2 ml harvested virus (or the equivalent of 
concentrate in T cell medium) was added to each well. The plate was then 
centrifuged at 4°C, 3000 g for 2 hours to attach viral particles to the RetroNectin 
layer.  
 
In the meantime, cultivated splenocytes were counted, centrifuged and supplied 
with fresh T cell medium containing 50 µM β-mercaptoethanol and 10 U/ml IL-2. 
Cell concentration was adjusted to 1 x 106/ml.  
 
When virus centrifugation was completed, remaining medium was removed, 
and 1 ml of splenocyte containing medium was added to each virus coated well. 
Additionally, one uncoated well was included as an untransduced control. 
Finally, 10 µl of mouse T-activator CD3/CD28 Dynabeads® were added to each 
well and the plate was centrifuged for another 30 minutes at 800 G and 32°C. 
 
After an incubation period of 24 hours, 1 ml of the second virus harvest was 
added to the matching well and spun down for 90 minutes at 800 G and 32°C. 
Cells were then placed in the incubator for 6 hours and afterwards 1 ml of 
medium was carefully removed and exchanged for fresh T cell Medium with 
50 µM β-mercaptoethanol and 10 U/ml IL-2. 
 
The following day and every second day hereafter, cells were centrifuged and 
concentration adapted to 1 x 106 cells/ml. From this day onward, cells were 
cultivated in T cell medium supplemented with 50 µM β-mercaptoethanol and 
50 ng/ml IL-15. 
 
Transduction efficiency was determined by flow cytometry between 24 and 
72 hours after second transduction. 
 
Transduced or untransduced expanded mouse T cells were never used for 
experiments later than eight days after splenocyte isolation.  
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6 Results 
6.1 Transduction of primary murine T cells with the OT-I TCR 
The unmodified ovalbumin specific T cell receptor, which served as a control 
throughout all experiments, was first cloned into the pMP71 vector. To achieve 
a high level of co-expression a bicistronic vector design was implemented. This 
was done by using a DNA sequence encoding for a p2A peptide.  
 
When T cells were transduced with this vector, the surface expression profile in 
flow cytometry showed only expression of the β-chain of the OT-I TCR. During 
further analysis, an intracellular staining of the transduced T cells was 
performed, revealing that the α-chain was indeed properly transcribed but 
retained within the cells (Figure 8).  
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A 
Untransduced T cells  OT-I TCR-transduced T cells 
  
B 
  
Figure 8: Flow cytometry analysis of transduced T cells. Surface (A) and intracellular (B) staining for 
vα2 and vβ5 of OT-I TCR-transduced (right) versus untransduced (left) T cells.  
 
To determine whether the order of the chains relative to the p2A linker impacts 
the expression profile, the chain order within the construct was reversed, so that 
now the β-chain preceded the p2A sequence.  
 
The reversed order not only led to a correct localization of the α-chain, but also 
left the localization of the β-chain unaffected (Figure 9). Therefore, this 
construct was used for all further transductions.  
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Figure 9: Flow cytometry analysis of transduced T-cells. Surface staining for vα2 of reversed OT-I 
TCR transduced (B) versus untransduced (A) T cells 
6.2 Design of cross T cell receptors 
On first approach the following two xTCR were constructed:  
 
Figure 10: Primary xTCR design: Linearized map of the OT-I const (A) and OT-I varia (B) xTCR within 
the vector, showing the location of the different domains and order in respect to the linker sequence. 
Chains are referred to as alpha or beta chains depending on their transmembrane domain.  
 
The two xTCR were named by the domain that was crossed. The one being the 
(OT-I) const xTCR (Figure 10 A) and the other the (OT-I) varia xTCR (Figure 
10 B). When referring to the chain subtype (alpha or beta) we decided to name 
an xTCR chain according to its transmembrane domain as this domain was 
never crossed in any of our constructs. That is, a chain carrying the alpha 
transmembrane domain would be referred to as OT-Iα varia or OT-Iα const 
depending on xTCR type. The same holds true for a chain carrying the tm beta 
domain (labelling shown in Figure 10) 
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6.3 Transduction of cross T cell receptors 
After transducing both variants of the xTCR into primary murine T cells, surface 
profiling in flow cytometry did not reveal any differential surface expression of 
the xTCR chains (Figure 11 A and Figure 11 B). Due to our previous 
experiences, we again performed intracellular staining which revealed 
differential expression only of Vα containing chains (Figure 11 C and Figure 
11 D). 
 
Figure 11: Flow cytometry analysis of xTCR transductions: Staining for vα2 (A, C) and vβ5 (B, D) of 
untransduced (red), const xTCR (green) and xTCR transduced (blue) T cells. The top half (A, B) shows 
surface staining, the bottom half intracellular (C, D) staining.  
 
To further investigate this issue, we decide to construct single chain vectors, so 
we could analyze surface expression independent of possible p2A residue 
interference.  
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6.4 Single chain xTCR vectors 
The following four chains were cloned into individual vectors, to allow single 
chain transduction of T cells: 
 
Figure 12: Single chain xTCR constructs: The two chains of each construct were separately cloned into 
one vector each yielding four new constructs, named according to their transmembrane domain and the 
crossing type (A-D). The individual chains were left unchanged.  
 
Again, we named the chains ‘const’ (Figure 12 A and Figure 12 B) or ‘varia’ 
(Figure 12 C and Figure 12 D) depending on the crossing type. A chain was 
referred to as α-chain (Figure 12 A and Figure 12 C) or β-chain (Figure 12 B 
and Figure 12 D) by its respective transmembrane domain. After transducing 
T cells, we then again performed surface and intracellular staining for vβ5 and 
vα2 followed by flow cytometry analysis.  
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Figure 13: Flow cytometry analysis of single chain xTCR transduction: Vα2 (A, C) and vβ5 (B, D) 
staining of the different xTCR single chains (color coding far right). The top half (A, B) shows surface 
staining, the bottom half (C, D) intracellular staining.  
 
None of the single chain constructs expressed on the surface (Figure 13 A and 
Figure 13 B), yet there was intracellular expression of the chains carrying a 
variable alpha domain (Figure 13 C). However, there was no detectable 
expression of any chain when staining for vβ5 (Figure 13 B and Figure 13 D). 
To further evaluate the impact of the linker sequence we proceeded by 
changing the order of our xTCR constructs within the vector.  
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6.5 Reversed xTCR double chain vectors 
We reversed the order of our xTCR chains as follows:  
 
Figure 14: Reversed xTCR vectors: In both the constant (A), as well as the variable (B) domain crossed 
TCR we reversed, we reversed the order of the chains relative to the linker sequence.  
 
Thereby, the large part of cleaved p2A peptide residue would now be attached 
to a tm β domain in both constructs (Figure 14 A and Figure 14 B). The 
following transduction results were obtained: 
 
Figure 15: Flow cytometry analysis of reversed xTCR transduction: Surface staining for vα2 of 
untransduced (red), reversed OT-I (blue), reversed const xTCR (green) and reversed varia xTCR (orange) 
transduced T cells.  
While the transduction efficiency was considerably below our usual transduction 
efficiency and the transduction efficiency seen in the unmodified TCR there was 
a clear surface expression of the OT-I varia xTCR. There was still no intra- or 
extracellular signal of vβ domains (data not shown). However, when further 
investigating the properties of the OT-I varia xTCR surface expression changed. 
Results 
 
 
 
-34- 
6.6 xTCR surface kinetic 
Through different experiments we observed that the surface expression of our 
OT-I varia xTCR was unstable (Figure 16).  
 
Figure 16: Flow cytometry analysis of xTCR surface expression over time: Surface staining for vα2 
on day 1 (left), day 3 (middle) and day 6 (right) after primary transduction of the different constructs (color 
coding far right).  
 
While on day one there was still a clear – albeit low –expression level, surface 
expression continuously decreased to baseline over the course of six day. To 
determine if this was a problem of location or expression on protein level, we 
performed intracellular staining.  
 
Figure 17 Flow cytometry analysis on day 6 after transduction. Intracellular staining for vα2 of the 
different constructs (color coding on the right). 
Despite no surface expression there was still a relatively high level of OT-I varia 
xTCR detectable within the cells. Here, also the OT-I const xTCR was 
expressed, though at a very low level (Figure 17). To further investigate this, we 
evaluated if surface expression could be enhanced by stronger binding of the 
xTCR chains.  
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6.7 Disulfide bond xTCR 
We derived this idea from early TCR engineering approaches, in which 
selective pairing was tried to be achieved by adding a disulfide bond between 
the two introduced chains. S. Dengl and W. Schaefer (Roche AG, Penzberg) 
kindly provided the protein structure simulations, identifying three possible 
domains for insertion of a disulfide bond (Figure 18).  
 
 
 
Figure 18: TCR structure simulation: Simulation of the OT-I TCR tertiary structure (A). Six possible sites 
were analyzed as candidates for disulfide bonds. Their CB atom distance and their degree of torsion was 
calculated (B).  The locations marked with green were chosen as best candidates. The red location is one 
commonly used as introduction site for disulfide chains and was therefore also realized. Provided by W. 
Schaefer and S. Dengl, Roche AG, Penzberg 
 
These three candidates were generated, resulting in a total of six new vectors, 
each now encoding for one of three possible disulfide bonds (Figure 19 A-C).  
   
Figure 19: Cysteine residue insertion locations: The two xTCR (left and right) vectors were changed at 
the marked locations, so that the given amino acids were replaced with cysteine. Thereby introducing the 
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three calculated disulfide bonds (dotted lines) between the two xTCR chains shown above. The locations 
shown in A-C correspond to the locations calculated in Figure 18 B. 
 
Again, these constructs were transduced into primary murine T cells to compare 
their surface expression profile to the respective OT-I xTCR. 
 
Figure 20: Flow cytometry analysis of disulfide bonds in xTCR const transductions: Surface staining 
for vα2 on day 2 after primary transduction with the different cysteinized const xTCR vectors (color coding 
on the right).  
 
In the case of the OT-I const xTCR, there was no detectable surface expression 
(Figure 20). In the case of the OT-I varia xTCR, there was detectable vα2 
surface expression. However, all three cysteine-modified xTCR variants did 
neither significantly increase surface expression on day two, nor show stable 
surface expression over time (Figure 21). By day five all transductions displayed 
baseline surface levels of vα2. 
Results 
 
 
 
-37- 
 
 
Figure 21 Flow cytometry analysis of disulfide bonds in xTCR varia transductions: Surface staining 
for vα2 on day 2 (A) and day 5 (B) after primary transduction with the different cysteinized varia xTCR 
vectors (color coding on the right).  
6.8 Elbow regions 
In our initial approach, the exact location of the domain switch was chosen 
within the elbow region, that is the linking sequence between constant and 
variable domain (Figure 22).  
 
Figure 22 Amino acid sequence of domain switch region: The underlined amino acids represent the 
putative elbow region and the black dash the location of the domain switch. The annotations on the side 
and the color coding indicates whether the amino acids belong to α- or β-chain.  
 
In an attempt to restore continuous surface expression of the xTCR, we 
changed the location of the domain switch so that the elbow region was left 
intact, that is we moved the location of the domain crossing to either edge of the 
elbow region (Figure 23). 
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Figure 23: Elbow region remodeling: Of our two initial xTCR (top) in which the elbow was ‘cut’ centrally 
we designed a total of four elbow modified xTCR in which the elbow region was left intact, named 
according to the domain the elbow region belongs to (A-D). 
 
This resulted in a total of four newly designed xTCR constructs, two for each 
domain crossing type (Figure 23 A and Figure 23 B, Figure 23 C and Figure 23 
D respectively). One in which the elbow was left uncrossed (Figure 23 A and 
Figure 23 D), and one where the elbow was crossed along with the adjacent 
domain (Figure 23 B and Figure 23 C). Despite several attempts, we were 
unfortunately not able to successfully clone the OT-I varia TCR with variable 
elbow (Figure 23 B). So, we decided to proceed with only three constructs. 
Again, we transduced the xTCR into primary murine T cells and analyzed by 
flow cytometry. 
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Figure 24: Flow cytometry analysis of transductions of xTCR with modified elbow region: Surface 
staining for vα2 on day 2 (A) and day 7 (B) after primary transduction of the different elbow modified xTCR 
vectors (color coding far right).  
 
We observed, that OT-I varia xTCR based modification showed significantly 
increased surface levels on day two (Figure 24 A). Yet, surface levels declined 
over time (Figure 24 B). The OT-I const based constructs showed no increased 
surface expression (Figure 24 A and Figure 24 B). When directly comparing the 
xTCR varia with and without modified elbow, we saw slightly higher expression 
levels in the changed elbow construct (Figure 25 A). Still, both transductions 
showed decreasing surface expression levels over time (Figure 25 B). 
 
Figure 25: Flow cytometry analysis of varia xTCR and elbow modified varia xTCR: Surface staining 
for vα2 on day 2 (left) and day 7 (right) after primary transduction with xTCR varia (red) or xTCR varia with 
modified elbow (blue).  
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7 Discussion 
7.1 Summary 
Taken together our experiments show that xTCR can be transduced into 
primary murine T cells resulting in initial surface expression of at least the 
β-chain of the OT-I varia xTCR. However, surface expression diminishes over 
time returning to baseline about seven days after transduction. At the same 
time, intracellular expression of vα carrying chains of both xTCR variants 
remains constantly high.  
 
We also observed that when using bicistronic vectors the order of the two 
inserts is relevant. More precisely, we found that whenever an alpha 
transmembrane domain was located N-terminally of the p2A linker, the 
corresponding chain did not translocate to the surface, despite being expressed 
intracellularly.  
 
Furthermore, surface expression of the OT-I varia xTCR depended on 
co-transduction of both chains. Single chain transduction did not result in 
surface expression. 
 
Additional disulfide bonds did not change surface expression profile of xTCR 
irrespective of their location within the xTCR.  
 
Variation of the crossing point within the elbow region slightly improved surface 
expression levels. However, decrease of surface expression over time could not 
be prevented.  
7.2 Linker sequence 
During all our experiments, we used the linker sequence known as p2A. 
2A peptide sequences mediate co-translational self-cleavage, without 
interfering with translation itself, thus leading to a stoichiometric 1:1 ratio of the 
two proteins (Szymczak et al. 2005). The cleaved peptide residue remains 
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linked to the translated proteins (Kim et al. 2011). All bicistronic transductions, 
in which an alpha transmembrane domain preceded the p2A linker, the 
N-terminal insert failed to translocate to the surface. When transducing the 
unmodified OT-I TCR, the β-chain translocates to the surface – irrespective of 
its relative position to the p2A linker. TCR translocation depends critically on 
correct assembly of both TCR chains and CD3 subunits (Bonifacino et al. 1989, 
Bonifacino et al. 1990). The assembly of CD3 subunits with the TCR mainly 
depends mainly on charged residues in the transmembrane domain of the TCR 
and CD3 chains (Call et al. 2002). A tm α domain that is not paired to CD3 
subunits is subjected to rapid intracellular degradation (Bonifacino et al. 1990). 
Therefore, the most plausible hypothesis that explains our observations seems 
to be, that the 19-aminoacid residue of p2A sequence interferes with a correct 
TCR-CD3 complex assembly. Due to its location, it seems most likely that the 
disruption occurs mainly between the TCRα and the CD3 subunits. 
Interestingly, this does not seem to be the case for the TCRβ.  
 
However, literature shows that p2A interference does not occur consistently in 
every TCR (Leisegang et al. 2008). It can therefore not be taken for granted 
that p2A residues never interfere with TCRβ-CD3 assembly. Even if surface 
expression of a TCR chain is not completely abrogated, it is possible for p2A 
residues to impair CD3 assembly. This can result in the native TCR 
outcompeting the exogenous TCR for CD3 recruitment and lowering its density 
on the surface, thus decreasing functional activity (Heemskerk et al. 2007, 
Jorritsma et al. 2007).  
 
Alternative strategies to avoid usage of p2A linkers include using internal 
ribosome entry sites (IRES) or performing double transductions with 
monocistronic vectors. However, both approaches suffer from drawbacks, as 
they cannot achieve a 1:1 stoichiometric ratio of both TCR chains, which in turn 
leads to suboptimal surface expression. Especially double transductions suffer 
from low transduction efficiency, while IRES linked vectors tend to 
underexpress the C-terminal insert (Leisegang et al. 2008). Therefore, while 
alternatives to p2A linkage are desirable, current substitutes are considered 
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inferior. Until better options arise, p2A linked bicistronic TCR vectors need to be 
assessed carefully on a case by case basis.  
 
7.3 Vβ5 epitope loss 
Throughout all our experiments and despite several modifications to the initial 
xTCR approach we were never able to detect the vβ5 epitope once the domains 
were switched. We considered several possible explanations. Two of which we 
believed to be the most relevant:  
 
For one, it is possible that the tertiary structure of the respective xTCR changes 
significantly over a larger area including the vβ5 epitope. If a change of the 
tertiary structure occurs at the epitope it is likely that major parts of the tertiary 
structure of this chain are affected. As opposed to immunoglobulins especially 
the β elbow region is considered more rigid (Bentley et al. 1995).  
 
However, if domain crossing affects the overall tertiary structure of one chain, 
one would expect an impact on the tertiary structure of the second chain. Yet, 
our results suggest that the structure of this chain is conserved, as the vα2 
epitope remains intact. Also, if the tertiary structure were the main issue then it 
would be likely that this can be reverted by choosing a better site to cross. But 
in our experiments three different crossing sites within the elbow region showed 
the same loss of detectability. And finally, immunoglobulins and TCR show high 
amounts of homology (Boulot et al. 1994) but domain switching has no major 
impact on the structure of immunoglobulins (Schaefer et al. 2011). 
 
Another explanation is that the vβ5 epitope lies exactly at the elbow region of 
the TCRβ. Unfortunately, the exact location and sequence of the vβ5 epitope 
are unknown so we were unable to prove this hypothesis. But given the 
arguments above, we deem this more likely to be true than a large change of 
tertiary structure. To be certain, further experiments need to be conducted, to 
either determine the vβ5 epitope or the crystal structure of xTCR.  
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7.4 Pairing properties 
Despite not being able to detect the vβ5 epitope, we were still able to draw 
conclusions about the pairing properties of our xTCR constructs. These became 
especially apparent when looking at our single chain transduction results:  
 
Through intracellular staining we could prove that at least the transduction of 
OT-Iα const and OT-Iβ varia was successful. However, there was no detectable 
surface expression. If these chains mispaired with endogenous TCR chains to 
form functional TCR-CD3 complexes, then these complexes would translocate 
to the surface (Bonifacino et al. 1989). As we detected no surface expression in 
our single chain experiments, we therefore concluded that none of our 
detectable crossed chains mispair with endogenous TCR chains.  
 
Furthermore, we could show that in our variable domain switch temporary 
surface expression is re-established, once we transduce with both chains. 
Together with our single chain data, this strongly indicates that the undetectable 
OT-Iα varia chain pairs with the detectable OT-Iβ varia chain and allows for 
correct CD3 subunit assembly, resulting in increased detectable vα2 epitope 
expression. So, despite one of our chains being undetectable, we can 
confidently assume that we did in fact achieve surface expression of both 
chains, as only correctly assembled TCR-CD3 complexes avoid intracellular 
retention and degradation (Bonifacino et al. 1990). By the same reasoning we 
can also assume, that the pairing properties of the constant domain switch were 
not sufficient to allow for a correct TCR-CD3 complex assembly.  
7.5 Kinetics of surface expression 
We were able to prove that xTCR can be transduced into primary murine T cells 
by intracellular flow cytometry staining. As p2A linked bicistronic vectors yield a 
1:1 stoichiometric ratio of both inserts (Szymczak et al. 2005), intracellular 
detectability of one chain, guarantees successful translation of both chains.  
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Our experiments also show that the OT-I varia xTCR is expressed on the 
surface of transduced T cells. The explanation why surface detectability of one 
chain proves successful surface expression of both chains was already given in 
7.4.  
 
However, surface expression was not permanent, but subject to some 
mechanism of degradation or internalization, leading to a continuous decrease 
of surface-detectable vα2 epitope. Eventually, surface expression returns to 
baseline after about seven days post transduction.  
 
The possibility that the transduction itself is unstable and gene expression is 
downregulated can be excluded, as there is durable intracellular expression of 
xTCR. Only surface expression diminishes.  
 
We were unable to find literature describing a continuous decrease of TCR 
surface expression post transduction. Literature consistently emphasizes that 
only completely assembled TCR-CD3 complexes translocate to the surface 
(Klausner et al. 1990). So, deterioration of TCR surface-levels cannot be 
explained by unsuccessful TCR-CD3 assembly. There are however, 
mechanisms described in literature that combined could potentially explain our 
observations:  
 
First, there is a concept of native TCR “outcompeting” an introduced TCR for 
CD3 recruitment (Bethune et al. 2016). The idea is based on the fact that the 
CD3 subunit pool is limited. If a second TCR is introduced into a cell, the 
concentration of TCR in the cell rises, while the number of available CD3 
molecules does not. Therefore, TCR dimers compete for CD3 assembly. If the 
native TCR shows a higher affinity to CD3 subunits, resulting in preferential 
pairing, then less TCR-CD3 complexes of the introduced TCR will form. In turn, 
this would lead to less surface translocation of the introduced TCR.  
 
Secondly, TCR-CD3 complexes get internalized and lysosomally degraded 
when T cells activate (Valitutti et al. 1997). During our transduction protocol, a 
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highly pure CD8+ T cell population is achieved by various forms of stimulation 
and activation.  
 
Taking together both of these effects, the following hypothesis seems plausible: 
xTCR show a lower affinity to CD3 molecules than the native TCR. Initially, 
however, the availability of intracellular CD3 subunits is high (Figure 26 A). 
Therefore, a number of xTCR-CD3 complexes form and translocate to the 
surface (Figure 26 B). Here, both xTCR- and native TCR-CD3 complexes get 
internalized and degraded due to T cell activation (Figure 26 C). This in turn, 
“consumes” more CD3 molecules than are produced, lowering the intracellular 
availability of CD3 subunits. However, the intracellular TCR levels remain high, 
as the cell produces two types of TCR. Due to the greater imbalance of TCR 
chains and CD3 subunits, the native TCR now increasingly outcompetes the 
xTCR for CD3 recruitment (Figure 26 C). This continuously lowers the amount 
of surface expressed xTCR and results in intracellular accumulation of xTCR 
(Figure 26 D).  
  
Figure 26: Hypothesis for xTCR surface kinetics: Each subfigure shows a T cell membrane with native 
(blue/red) TCR and xTCR (green/orange), as well as CD3 molecules (pink, simplified). First, intracellular 
levels of CD3 are high (A), allowing xTCR surface expression, but lowering CD3 levels (B). Then, surface 
TCR-CD3 complexes are degraded and replaced by TCR-CD3 complexes. Due to low levels of CD3 the 
native TCR outcompetes the xTCR for CD3 recruitment (C). Finally, only native TCR is expressed on the 
surface, while the xTCR accumulates intracellularly (D).  
 
Though plausible by literature, this effect has not been previously described and 
remains speculative. To prove this, further experiments need to be conducted, 
such as immunoprecipitation of xTCR and CD3 subunits.  
 
Following this hypothesis, the process of declining xTCR surface expression 
would happen particularly fast, if xTCR gets internalized at a higher rate, than 
the native TCR. However, when adding additional disulfide bonds to the xTCR 
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no stabilization of surface expression was observed. Suggesting that the kinetic 
of internalization is not influenced by disulfide linking of TCR chains.  
7.6 Elbow region and intrachain domain interactions 
To gain further insight into the mechanisms of TCR assembly and surface 
translocation, we conducted further literature research on TCR structure. As it 
turns out, there are significant differences in the tertiary and quaternary 
structure of TCR as opposed to immunoglobulins. Despite being homologous 
for a large part of their structure (Boulot et al. 1994), there are regions that show 
very distinct features: In 1995 the structure of the TCR β-chain was unraveled 
through crystallography (Bentley et al. 1995). It turned out, that while the vβ 
domain was highly homologous with the vL domain, the cβ domain showed a 
more polarized surface. The most significant difference appeared to be the 
interaction of the variable and constant domain within the β-chain. There was a 
lot of covered surface area and close interaction between the domains. It was 
also described that the elbow region of the β-chain would hence be very rigid 
and lack flexibility. 
 
Also we discovered that a similar approach had been tried before: In 1993 
Casorati et al. performed what they described as “αβ V-J domain shuffling” 
(Casorati 1993). In their approach, they used the TCR derived from the mouse 
T helper hybridoma 16.2.D, which is an influenza (H1N1) specific TCR. The 
TCR chains created were of the structure Vα-Cβ and Vβ-Cα respectively. The 
transduction was performed in TCR-deficient 58αβ- hybridoma cell lines. Four 
double-transductions were performed:  
 
Figure 27: Double transductions performed by Casorati et al.: Vα-Cα and Vβ-Cβ (A), Vβ-Cα and Vβ 
Cβ (B), Vα-Cα and Vα-Cβ (C), Vβ-Cα and Vα-Cβ (D). 
 
Some of their results align with what we saw in our approach: Except in the 
unmodified double-transduction, no surface expression was achieved, but they 
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saw intracellular accumulation. They also performed co-precipitation, proving 
that there was no intracellular assembly of “shuffled” TCR.  
 
Figure 28: Expression results from Casorati et al.: Except the unmodified TCR (A), no other double 
transductions yielded TCR surface expression (B-D) 
 
In our approach, however we observed some translocation to the surface, 
suggesting, that these results do not uniformly apply to all TCR types and 
domain crossing points. As it appeared that at least to some extent the rigidity 
of the elbow was responsible for their observations, we reasoned that the exact 
location of the domain switch within the elbow region might be crucial.  
 
In a final approach, we designed another three constructs with different 
crossing points in the elbow region, as described in 6.8. While there was no 
significant improvement of surface expression, there was also no loss thereof. 
This indicates, that at least in our model, the domain switch approach is 
somewhat robust to changing the location of the crossing point. However, 
despite many modifications, we were unable to achieve durable surface 
expression of xTCR chains.  
 
Due to the partial discrepancy between results in literature and our results, the 
question arises whether possibly certain subtypes of TCR allow for domain 
crossings while others do not. To further investigate this, additional TCR 
crossing would need to be performed and their surface expression assessed.  
7.7 Domain-swapped T cell receptors 
Recently a similar approach to modifying TCR was published (Bethune et al. 
2016). Instead of choosing a domain switch of variable or constant domain, the 
following three domain switches were used:  
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Figure 29: Domain switches used by Bethune et al.: Domain switch at the V-C junction (A), domain 
switch at the junction between constant domain and transmembrane domain connecting peptide (B) and 
domain switch at the junction between connecting peptide and transmembrane domain (C). 
 
While the first approach (Figure 29 A) matches our xTCR varia approach, the 
other two are distinct (Figure 29 B and Figure 29 C). The given publication 
describes that surface expression was only achieved in the latter two 
approaches while the first approach failed. These two “domain swapped TCR” 
(dsTCR) not only showed avidity in dextramer staining, but also retained 
functional capacity in vivo: OT-I dsTCR transduced T cells were able to reject 
an ovalbumin overexpressing thymoma line when injected into mice in the same 
way T cells transduced with the unmodified OT-I TCR did. Furthermore, dsTCR 
chains did not show surface expression when only one dsTCR chain was 
co-transduced with an unmodified TCR chain into Jurkat T cells. To also 
exclude mispairing with other native TCR, dsTCR chains were labeled with an 
N-terminal myc and V5-tag respectively. Then single chains were transduced 
into primary T cells and detectability of the tags was measured. Tagged 
unmodified TCR chains showed surface expression due to mispairing, however 
no surface expression of the tags was detected when using dsTCR chains, 
proving that mispairing does not occur even when there is a broad variety of 
native TCR chains to pair with.  
 
Finally, the given publication used the TI-GVHD model described in 3 (Bendle et 
al. 2010) to examine dsTCR in an in vivo mispairing model. In concordance with 
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the other results, OT-I dsTCR transduced T cells did not cause auto reactivity 
as seen with unmodified OT-I TCR transduced T cells.  
 
Furthermore, the dsTCR approach was validated with a variety of different TCR, 
showing that the concept is easily applicable to a wide range of TCR without 
further adjustments.  
 
However, some limitations to the dsTCR model were also seen: Often the 
surface expression of dsTCR was significantly lower than that of the unmodified 
TCR. Bethune et al. reasoned, that the native TCR “outcompete the dsTCR for 
CD3 recruitment”. To optimize this, they showed that when co-transducing with 
shRNA (Bunse et al. 2014), they could significantly increase surface expression 
by decreasing the level of endogenous TCR. The publication also argues that 
as the switching domains at the V-C junction might improve pairing properties 
with CD3 as the constant domains would not be switched relatively to the 
transmembrane domains. However, they state that despite this being possible 
in antibodies (Schaefer et al. 2011), this attempt fails in TCR in concordance 
with what we observed in our xTCR approach.  
7.8 Conclusions and outlook 
Despite different attempts, we were unable to achieve stable surface expression 
of xTCR. However, we could clearly show that the varia xTCR shows temporary 
surface expression. Our results in combination with the data of Bethune et al. 
summarized in the previous chapter, give convincing evidence for domain 
crossing to successfully prevent mispairing and its detrimental side effects.  
 
Bethune et al. have furthermore shown that when crossing the transmembrane 
domain instead of variable or constant domain that surface expression is 
consistently achieved through a variety of TCR and that these dsTCR are 
functional in vitro and in vivo. Therefore, providing a relevant alternative to 
currently established TCR modifications such as single chain TCR.  
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However, an xTCR with a crossed variable domain still remains desirable as it 
would ensure a more physiological orientation of CD3 subunit assembly 
(Bethune et al. 2016). Especially, as the detailed consequences of crossing 
transmembrane domains on TCR signaling are unknown and the potential side 
effects of ACT are potent and dangerous (Schumacher 2002, Riechelmann et 
al. 2007). 
 
It remains unclear, however, whether the xTCR approach described in this 
thesis is feasible or not. To further assess feasibility, further investigation on 
structure and pairing properties of xTCR are needed, which require techniques 
such as protein crystallography and immunoprecipitation. Yet, such techniques 
were beyond the scope of this thesis, where the aim was a basic 
characterization of xTCR.  
 
In light of the growing importance and efficacy of ACT, it becomes increasingly 
relevant to improve the safety of this therapy. For gtACT to move beyond a last 
line approach, it is imperative to have a repertoire of safe TCR modifications at 
disposal. The development and further examination of crossed or “domain 
swapped” TCR is a decisive step in this direction.  
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9 Appendix 
9.1 List of abbreviations 
ACT Adoptive cell therapy 
CD3x CD3 subunit x 
CDx Cluster of differentiation number x 
Cα Constant alpha domain 
Cβ Constant beta domain 
DMEM Dulbecco's Modified Eagle's medium 
DMSO Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
dsTCR Domains swapped TCR 
FBS Fetal bovine serum 
g Gram or gravity of earth 
gtACT Gene transfer-based adoptive cell therapy 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
IL-x Interleukin number x 
kb Kilobase pairs 
l Liter 
LB Lysogeny broth  
M Molar 
MDSC Myeloid-derived suppressor cells 
MHC I Major histocompatibility complex class I 
min Minutes 
mol Mole (unit) 
OT-I TCR MHC class I-restricted, ovalbumin-specific TCR 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
RPMI 1640 Roswell Park Memorial Institute medium 
TAE TRIS-Acetate-EDTA 
TBI Total body irradiation 
TCR T cell receptor 
TCRα TCR alpha chain 
Appendix 
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TCRβ TCR beta chain 
TI-GVHD TCR gene transfer-induced graft-versus-host disease  
TIL Tumor infiltrating lymphocyte 
TM Transmembrane domain 
U Units 
V Volts 
vH Variable heavy chain domain 
vL Variable light chain domain 
Vα Variable alpha domain 
Vβ Variable beta domain 
xTCR Cross TCR 
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